Omid

Quick links to important sections

Omid

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omid

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton-Pump Inhibitor (PPI)
General purpose Sustained reduction of stomach acid
Origin Synthetic, substituted benzimidazole

What Type of Medicine is Omeprazole?

Omid is the commercial designation for a medication containing the active substance Omeprazole, the foundational compound of the Proton-Pump Inhibitor (PPI) pharmacological class. This type of medicine is globally recognized and supported by extensive pharmacological studies for its ability to achieve profound and sustained suppression of gastric acid secretion. Chemically, Omeprazole is a synthetic, substituted benzimidazole compound. The generic formulation of Omeprazole is available for both prescription-only (Rx) and specific over-the-counter (OTC) use, depending on the regulatory context.


Composition and Physical Form

The core composition of Omeprazole is a racemate, meaning it includes two mirror-image chemical forms. Due to the compound's inherent instability, it is manufactured as a specialized enteric-coated preparation to ensure stability. This protective base/vehicle is packaged into delayed-release capsules or tablets, with formulations also available as granules for oral suspension. This deliberate design ensures the medication passes through the harsh acidic environment of the stomach intact, allowing it to be absorbed in the small intestine for systemic action.


General Purpose: What is Omeprazole Used For?

The general purpose of this medication is to effectively manage acid-related disorders characterized by gastric acid hypersecretion. Clinical experience confirms its effectiveness in controlling acidity. By facilitating a continuous acid production blockade, Omeprazole helps relieve the associated burning and irritation. This action creates an optimal environment for the healing of tissues that have been damaged or inflamed by prolonged exposure to strong stomach acid.

Regulatory References

  1. NIH MedLinePlus: Omeprazole

What side effects are possible with Omid?

Possible Side Effects and Safety Information: Omid

Omid, which typically contains the active ingredient omeprazole (a proton pump inhibitor), is generally well-tolerated. However, like all medications, it can cause side effects. Most common side effects are usually mild and temporary.


Common Side Effects

Commonly reported adverse effects include headache, abdominal pain, nausea, vomiting, diarrhea or constipation, and flatulence (gas). If these effects persist or worsen, consult your healthcare provider.


Serious or Long-Term Safety Concerns

In rare cases or with prolonged use (typically over a year), Omid may be associated with more serious risks:

  • Bone Fractures: Long-term, high-dose therapy may increase the risk of hip, wrist, or spine fractures. This risk is higher in older adults.
  • Nutrient Deficiency: Prolonged use can lead to reduced absorption of vitamin B12 and magnesium (hypomagnesemia). Low magnesium levels can be serious, potentially causing irregular heart rhythm or seizures.
  • Infections: There is a slightly increased risk of certain gastrointestinal infections, including Clostridioides difficile-associated diarrhea.

Seek immediate medical attention if you experience signs of a serious reaction, such as a severe rash, blistering skin (a sign of a severe skin reaction like Stevens-Johnson syndrome), difficulty breathing, swelling of the face, or new or worsening joint pain.


Important Safety Precautions

Consult a doctor before taking Omid if you have severe liver problems or a history of lupus. Omid may interact with other medicines, including certain blood thinners (like warfarin or clopidogrel), HIV medications (such as rilpivirine), and diuretics. Always inform your physician of all medications and supplements you are taking.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Omid

Overdose Scope

Domain Official Regulatory Information
Documented overdose presentations Overdose is typically associated with transient and not clinically serious effects, including headache, nausea, vomiting, diarrhea, abdominal pain, drowsiness, and confusion [FDA Label].
Physiological systems affected (as stated in label) Gastrointestinal, Central Nervous System, Cardiovascular (tachycardia), and Hepatic (transient elevation of liver enzymes).
Dose-related or exposure-related factors (if applicable) Limited acute toxicity experience; massive single ingestion is generally associated with the mild, transient symptoms described.
Population-specific overdose notes (if applicable) No specific, differentiated symptoms for overdose are documented for pediatric or geriatric populations in official labeling.
Emergency-response statements (as written in official documents) Seek immediate medical attention or contact a Poison Control Center right away [NIH/MedlinePlus].
When immediate medical help is required (label-derived phrasing only) Immediate medical help is required in the event of an overdose or suspected overdose.

Overdose Classifications (High-Level)

Classification Official Regulatory Wording / Basis
Severity classification (as defined in official documents) Classified as generally transient; acute liver failure is cited as a rare, severe outcome.
Regulatory basis (EMA / FDA / etc.) U.S. FDA DailyMed/Label, European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents) Treatment is confined to symptomatic and supportive measures because no specific antidote is known, and the substance is not readily dialyzable.

Resulting Overdose Structure

Official overdose statements:

  • In most overdose cases, symptoms are transient and include gastrointestinal and CNS effects as described in regulatory documents.
  • Management should be symptomatic and supportive treatment only, as there is no specific antidote known.
  • Authorities strictly mandate that individuals seek immediate medical attention or contact a Poison Control Center if an overdose is suspected.
  • Close clinical observation and monitoring may be required following significant ingestion.

Connection to the Overall Overdose Profile

Regulatory documents strictly define the overdose profile by listing the expected, non-life-threatening clinical manifestations and explicitly stating that no specific antidote is known. The severity is generally reported as transient; however, the lack of a known countermeasure dictates that regulators require immediate contact with emergency services for supportive care, clinical observation, and symptomatic management.

Therapeutic Uses of Omid

Omid, commonly known as omeprazole, is a medicine generally used for managing various conditions characterized by heightened symptoms. Its primary use involves easing discomfort and providing supportive relief in contexts where tissue repair is a clinical goal.


Addressing Acid-Related Discomfort and Reflux

This medication is commonly used to help with symptom clusters that may become intense or disruptive, particularly those that interfere with daily comfort. These include heartburn and acid regurgitation caused by Gastro-esophageal Reflux Disease (GERD). Omid provides support that helps ease the overall symptom burden during periods of heightened symptoms.

Omid may assist with a range of core conditions, including active duodenal and gastric ulcers, erosive esophagitis, and pathological hypersecretory conditions like Zollinger-Ellison Syndrome. The medicine contributes to improved comfort during these episodes by providing supportive relief when symptoms interfere with routine activities.

“Omid helps address symptom clusters that may become intense or disruptive, and contributes to functional stability.”


Quick Fact: Support for Heartburn Symptoms

Omid is relevant in contexts marked by increased discomfort or tension. It is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed to support the patient during difficult episodes by easing distress.

Regulatory References

  1. European Medicines Agency (EMA) product overview

Eligibility and Restrictions for Use

Official regulatory documents define specific population eligibility boundaries for Omid (omeprazole).

The medicine is absolutely contraindicated in populations with a known hypersensitivity to omeprazole or any drug belonging to the substituted benzimidazole class. Co-administration with the antiretroviral medications nelfinavir or rilpivirine is also strictly prohibited, representing a formal drug-drug interaction contraindication.

Adults and older adults are generally eligible for use. However, use in the pediatric population is not established and generally unauthorized for infants under one year of age. Children one year old and older are conditionally eligible for limited treatment based on minimum weight thresholds.

Specific physiological states impose regulatory restrictions: populations with severe hepatic impairment require conditional use due to altered drug exposure. While those with renal impairment are eligible for standard use, use during pregnancy is conditional, and it is not recommended for the breastfeeding population. Regulatory labels further require that the possibility of a gastric malignancy must be excluded before starting therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omid’s official interaction profile is characterized by two primary mechanisms: CYP2C19 enzyme inhibition and gastric pH elevation, which results in altered exposure of co-administered substances.


Formally Contraindicated Combinations

Co-administration is strictly contraindicated with the antiretrovirals Nelfinavir and Rilpivirine. This restriction is due to Omeprazole's effect of significantly increasing gastric pH, which reduces the absorption and plasma concentrations of these medicines, leading to a loss of their therapeutic effect.


Documented Exposure Alterations

  • CYP2C19 Inhibition: Omeprazole is a moderate inhibitor of the CYP2C19 enzyme. This metabolic interference reduces the formation of the active metabolite of the antiplatelet medicine Clopidogrel, diminishing its activity. Regulatory bodies advise discouraging concomitant use.
  • Increased Levels: Omeprazole may increase the systemic exposure of other drugs metabolized by CYP enzymes, including Cilostazol, Phenytoin, and Digoxin. Conversely, co-administration with the strong inhibitor Voriconazole can increase omeprazole's own plasma levels.
  • Reduced Levels: Concomitant use with enzyme inducers like Rifampin or the herbal product St John's Wort may reduce Omeprazole concentrations.

Timing and Procedural Constraints

The interaction profile includes mandatory timing restrictions:

  • High-Dose Methotrexate: The official label advises considering temporary withdrawal of omeprazole during high-dose Methotrexate administration, as co-use may elevate and prolong Methotrexate serum concentrations.
  • Diagnostic Testing: Omeprazole must be withheld for at least 14 days before testing blood levels of Chromogranin A (CgA), as the medication interferes with the results of this diagnostic procedure.

Population-Specific Notes

Regulatory documents highlight that individuals classified as CYP2C19 poor metabolizers demonstrate a significantly higher systemic exposure (AUC) to omeprazole, which heightens the risk for CYP2C19-mediated drug interactions.

Mechanism of Action

Mechanism of Action: How Omid Works

Omid's action is defined by its interaction with receptor- or enzyme-mediated signaling within targeted biological systems. The compound functions as a specific pathway modulator, altering the kinetics of key molecular components. This primarily occurs via a mechanism of competitive binding at a defined intracellular target , thereby initiating or suppressing the early molecular steps that govern downstream cellular activity.

This molecular interaction subsequently influences mechanistic cascades that include complex feedback mechanisms. Omid's presence reduces the activity of specific signaling mediators, leading to a direct modification of the physiological response output. At the system level, this results in the adjustment of cellular output and a non-evaluative alteration of overactive or dysregulated physiological processes within the targeted tissues, maintaining focus strictly on the pharmacodynamic consequence.

Dosage and Administration Information

How to Use Omid — Official Administration Guidelines

This section outlines the official usage instructions for Omid products, strictly according to regulatory prescribing information. Due to the existence of distinct pharmaceutical products sharing related names (e.g., Omisirge, Omidria), administration details are highly dependent on the specific formulation being used.

Administration Scope

Omid formulations are typically administered as a single-dose or single-event procedural treatment and are not intended for daily, routine self-administration.

Administration Entity Cell Therapy (Omisirge) Intraocular Concentrate (Omidria)
Route of Administration Intravenous (IV) Infusion Intraocular Use
Dosing Schedule Single dose based on minimum cell counts per kg of body weight Single-event dose based on fixed dilution ratio (e.g., 4 mL concentrate into 500 mL irrigating solution)
Age-Group Rules Adults and pediatric patients ge 12 years Adults only

Preparation and Procedural Rules

Preparation of Omid requires specific handling and timing. For cell therapies, the product must be thawed and diluted with designated infusion solutions immediately prior to administration. The two required cell fractions must be infused sequentially on the same day, with strict time limits imposed on the post-dilution infusion period. Administration must take place under the supervision of a physician experienced in the relevant therapeutic area, such as hematopoietic stem cell transplants.

For the intraocular concentrate, the product must be diluted into the designated ophthalmic irrigating solution and is never to be used in its concentrated form. This solution is then used during the specified surgical procedure. Due to the single-event nature of both products, instructions for a missed dose are not applicable.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Omid

Evidence from Studies for Reflux and Acid Damage (GERD and Erosive Esophagitis)

Omid was studied for its use in research exploring acid-related conditions like Gastro-esophageal Reflux Disease (GERD). These studies primarily involved short-term Randomized Controlled Trials (RCTs) designed to explore how patient-reported outcomes related to discomfort and daily functioning changed over a few weeks. For Erosive Esophagitis (EE), research examined outcomes related to healing of damage in the food pipe, as confirmed by endoscopy. Findings from these trials describe patterns observed where symptom relief and tissue healing were monitored over defined time intervals. Long-term certainty regarding sustained healing and prevention of relapse in all populations is not fully established.

Evidence from Studies for Ulcers and Bacterial Eradication

Omid was evaluated in research for active peptic ulcers and as a component of multi-drug regimens to address the H. pylori bacteria. Short-term RCTs were used to examine whether ulcers closed completely. For H. pylori absence, research describes the reported rates when Omeprazole was studied in combination with specific antibiotics. A key research limitation frame is that evidence for eradication is based entirely on multi-drug combination studies.

Evidence in Special Research Populations and Gaps

Research has explored the use of Omeprazole in certain groups, particularly pediatric cohorts (infants and older children). However, data for certain groups remain insufficient, and subgroup findings are uncertain regarding long-term outcomes for all older adult patients. The majority of RCTs have limited follow-up durations, meaning long-term certainty is not fully established for all outcomes. Research provides context but not individual predictions, and research is ongoing to address remaining evidence gaps.

Frequently Asked Questions (FAQ)

Common questions about Omid (FAQ)


Q: Is Omid used for things other than its primary listed purpose?

Yes, official regulatory documents describe Omid's use for a variety of acid-related conditions. These include the healing and maintenance of Erosive Esophagitis and the treatment of gastric and duodenal ulcers. It is also used in the management of gastric acid hypersecretion conditions, such as Zollinger-Ellison Syndrome.


Q: Does alcohol interact negatively with Omid?

Official documentation for Omid does not list a formal, clinically significant drug-alcohol interaction that requires restriction.


Q: What are the known risks of stopping Omid suddenly?

The antisecretory effect of Omid is long-lasting, even after the medicine is discontinued. According to pharmacodynamics information, gastric acid secretory activity gradually returns to baseline over approximately three to five days after the medication is stopped.


Q: What is the typical timeframe for seeing the full effect of Omid?

The antisecretory effect of Omid begins within one hour of administration, with the maximum effect occurring within two hours. Official documents state that the full inhibitory effect on acid production is typically achieved after approximately four days of repeated once-daily dosing.


Q: Do studies suggest Omid is effective across different patient groups?

Research has included studies in pediatric cohorts and older adults. However, regulatory documents indicate that long-term certainty regarding sustained outcomes in all older adult patients is not fully established, and research continues in these populations.


Q: Are there any requirements for regular monitoring while on Omid?

Regulatory safety information notes that prolonged use may be associated with reduced absorption, which can result in low Vitamin B12 and low magnesium (hypomagnesemia) levels. Official documentation advises that patients may require regular monitoring for these conditions.


Q: Why does Omid need to be taken consistently?

Omid functions as a gastric acid-pump inhibitor that blocks the final step of acid production by irreversibly binding to an enzyme system. The full inhibitory benefit on acid production is generally achieved and maintained with repeated once-daily dosing, as the medication's effect is cumulative.


Q: Is it common to feel tired when starting Omid?

The most commonly reported adverse effects include headache and abdominal pain. While not among the most common, adverse reaction reports have included instances of effects such as dizziness and drowsiness experienced by some patients.


Q: Can over-the-counter pain relievers be taken with Omid?

Official drug interaction documents do not list formal, specific contraindications or significant interactions with common over-the-counter pain relievers such as acetaminophen or ibuprofen.


Q: Are there specific foods or beverages that should be limited while taking Omid?

Official documentation does not list specific foods or beverages that are formally contraindicated due to a direct drug interaction.


Q: Are older adults typically prescribed a lower amount of Omid?

In older adults, the typical starting dose is generally described as the same as the standard adult dose. Official regulatory information indicates that dose adjustments may be considered based on overall health and function, particularly in cases of severe hepatic impairment.


Q: If a dose of Omid is missed, what is the general guidance?

If a scheduled daily dose is missed, regulatory patient information advises taking the dose as soon as possible. If it is almost time for the next scheduled dose, the information states to take only that next dose, and never to take double or extra doses.


Q: Does taking Omid with food change how it is absorbed?

Official administration instructions state that the delayed-release capsules should be taken before eating. In contrast, the delayed-release tablets may be taken either with food or on an empty stomach, depending on the specific product formulation.


Q: What kind of research has been done on Omid in specific patient populations?

Research has included studies in specific groups such as pediatric cohorts (children one year of age and older) and older adult patients.


Q: Can Omid be taken with coffee or caffeine?

Official documentation does not list a formal, clinically significant drug interaction with caffeine or coffee.


Q: Is it normal to feel a mild headache when starting Omid?

Headache is listed in the official documentation as one of the commonly reported adverse effects of the medication.


Q: Does Omid cause an increase in sensitivity to sunlight?

Post-marketing surveillance reports have described instances of increased sensitivity of the skin to sunlight (photosensitivity) as a possible adverse effect.


Q: Is Omid a prophylactic (preventative) or a treatment?

Official uses include both the management of active acid-related disorders (acting as a treatment) and the prevention of relapse of healed tissue damage (acting as a prophylactic use) in certain specified conditions.


Q: Why is Omid sometimes prescribed at different strengths?

Different strengths and dosing regimens are necessary because the required dose depends on the specific condition being managed. For example, the dose for typical GERD management differs from that required for Zollinger-Ellison Syndrome, and doses may also be adjusted based on the patient's body weight.


Q: What does the term 'half-life' mean in relation to Omid?

The plasma half-life refers to the time it takes for the concentration of the drug in the plasma to be reduced by half. For Omid (Omeprazole), the plasma half-life is very short, typically less than one hour.

How should Omid be stored and disposed of?

The official storage and disposal requirements for Omid (Omeprazole delayed-release product) are strictly defined to protect the medicine's stability and ensure safety.

Storage Conditions

Omid must be stored at a controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The container must be kept tightly closed and stored in its original container to actively protect the product from light and moisture. The product does not require refrigeration. All medicine must be kept out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Omid should be disposed of via an authorized drug take-back program where available, as specified by regulatory agencies. If a take-back option is not accessible, the product is not on the FDA's flush list and must be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being placed in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Omid found in:

A-Z Index: